tbuckley/cabot-search huggingface dataset:
Cross-sectoral genomic surveillance reveals a lack of insight in sources of human infections with Shiga toxin-producing Escherichia coli, the Netherlands, 2017 to 2023
Authors: Ingrid HM Friesema, Menno van der Voort, Ben Wit, Angela HAM van Hoek, Maaike JC van den Beld, Coen van der Weijden, Eelco Franz
Journal: Eurosurveillance (2024)

Shiga toxin-producing Escherichia coli (STEC) is a zoonotic pathogen associated with illness ranging from mild diarrhoea to haemolytic uremic syndrome (HUS) or even death. Cross-sectoral data sharing provides an opportunity to gain insight in reservoirs and sources of human infections and starting points for pro-active measures. Nevertheless, phylogenetic clustering of STEC strains from animals, food and human cases is low in the Dutch surveillance system. This is partly due to the substantial contribution of international travel and person-to-person spread in the STEC epidemiology. Furthermore, some STEC strains causing disease in humans may have a human reservoir. Although the main reservoirs and sources are included in the Dutch monitoring programmes, some animals and food products may be under-recognised as potential sources of human infections. More effort in investigating the role of other reservoirs beyond the well-known can provide a better understanding on STEC ecology in general, improving surveillance and source attribution, and ultimately provide better guidance for monitoring and source finding. This also implies having good diagnostics in place and isolates available for typing. Therefore, on the human side of the surveillance, the decision has been made to start isolating STEC at national level.
COP29: incremental but insufficient progress on climate finance
Authors: None The Lancet Regional Health – Europe
Journal: The Lancet Regional Health - Europe (2024)

At COP29 in Baku, Azerbaijan, which was extended until Nov 24, 2024, climate finance took centre stage. Dubbed the "finance COP," the conference's conclusion was delayed as nearly 200 countries struggled to agree on the New Collective Quantified Goal (NCQG)—a climate funding plan for the next decade to replace the US$100 billion annual target expiring in 2025. The NCQG is seen as crucial to achieving the Paris Agreement's aim of limiting global warming to 1.5 °C.
Correction: Consensus Statement: Recommendations on Actionable Biomarker Testing for Thyroid Cancer Management
Authors: Ozgur Mete, Andrée Boucher, Kasmintan A. Schrader, Omar Abdel-Rahman, Houda Bahig, Cheryl Ho, Olfat Kamel Hasan, Bernard Lemieux, Eric Winquist, Ralph Wong, Jonn Wu, Nicole Chau, Shereen Ezzat
Journal: Endocrine Pathology (2024)
Persistent response to combination therapy of pemigatinib and chemotherapy in a child of combined hepatocellular-cholangiocarcinoma with FGFR2 fusion
Authors: Guo-qian He, Qing Li, Xiao-yu Jing, Jian Li, Ju Gao, Xia Guo
Journal: Molecular Cancer (2024)

Combined hepatocellular-cholangiocarcinoma (cHCC-CCA), an extremely rare and underinvestigated subtype of primary liver cancer in children, generally has a poor prognosis and greater aggressiveness. Histological diagnosis of cHCC-CCA is difficult because of its diverse components, including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). cHCC-CCA shares some genetic alterations with HCC and CCA. However, only a few studies on genetic alterations in fibroblast growth factor receptor 2 (FGFR2) in cHCC-CCAs have been reported in adults. Therapeutic strategies for cHCC-CCAs are limited, and surgical resection is the only standard of care. No standard systemic treatment has been established for unresectable cHCC-CCAs. Herein, we report a rare case of a 14-year-old female patient diagnosed with unresectable cHCC-CCA with multiple liver masses and metastases to the lungs, lymph nodes and peritoneum. Next-generation sequencing (NGS) has identified an FGFR2-PRDM16 fusion, which has not been previously reported as a common FGFR2 fusion. The blood tumour markers alpha-fetoprotein (AFP) and carbohydrate antigen 19 - 9 (CA19 - 9) were both elevated. The patient was treated with pemigatinib (a selective FGFR inhibitor) in combination with Gemcitabine and Cisplatin at our hospital. After three cycles of the combination therapy, the patient achieved a partial response and normalization of tumor markers. After seven cycles of combination therapy, the patient achieved stable disease with the best response. Subsequently, the patient was administered received pemigatinib and gemcitabine. As of the last follow-up date, the patient has survived for 26 months. To the best of our knowledge, this is the first reported rare case of unresectable cHCC-CCA with FGFR2-PRDM16 fusion in a child successfully treated with a combination of pemigatinib and chemotherapy as a first-line regimen. This treatment combination may be effective and safe for patients with unresectable cHCC-CCAs.
Chimeric antigen receptor macrophages targeting c-MET(CAR-M-c-MET) inhibit pancreatic cancer progression and improve cytotoxic chemotherapeutic efficacy
Authors: Huaijin Zheng, Xinzhe Yang, Nan Huang, Shangqin Yuan, Jiayi Li, Xudong Liu, Qing Jiang, Shanshan Wu, Yue Ju, Jorg Kleeff, Xiushan Yin, Quan Liao, Qiaofei Liu, Yupei Zhao
Journal: Molecular Cancer (2024)

Pancreatic ductal adenocarcinoma (PDAC) is one of the most malignant tumors. Macrophages are abundant in the tumor microenvironment, making them an attractive target for therapeutic intervention. While current immunotherapies, including immune checkpoint inhibition (ICI) and chimeric antigen receptor T (CAR-T) cells, have shown limited efficacy in pancreatic cancer, a novel approach involving chimeric antigen receptor macrophages (CAR-M) has, although promising, not been explored in pancreatic cancer. In this study, we first investigated the role of CAR-M cells targeting c-MET in pancreatic cancer. The effectiveness and rationality of c-MET as a target for CAR-M in pancreatic cancer were validated through bioinformatic analyses and immunohistochemical staining of samples from pancreatic cancer patients. We utilized flow cytometry and bioluminescence detection methods to demonstrate the specific binding and phagocytic killing effect of CAR-M on pancreatic cancer cells. Additionally, we observed the process of CAR-M engulfing pancreatic cancer cells using confocal microscopy and a long-term fluorescence live cell imaging system. In an in situ tumor model transplanted into NOD/SCID mice, we administered intraperitoneal injections of CAR-M to confirm its inhibitory function on pancreatic cancer. Furthermore, we validated these findings in human monocyte-derived macrophages (hMDM). Bioinformatics and tumor tissue microarray analyses revealed significantly higher expression levels of c-MET in tumor tissues, compared to the paired peritumoral tissues, and higher c-MET expression correlated with worse patient survival. CAR-M cells were engineered using human monocytic THP-1 cell line and hMDM targeting c-MET (CAR-M-c-MET). The CAR-M-c-MET cells demonstrated highly specific binding to pancreatic cancer cells and exhibited more phagocytosis and killing abilities than the pro-inflammatory polarized control macrophages. In addition, CAR-M-c-MET cells synergized with various cytotoxic chemotherapeutic drugs. In a NOD/SCID murine model, intraperitoneally injected CAR-M-c-MET cells rapidly migrated to tumor tissue and substantially inhibited tumor growth, which did not lead to obvious side effects. Cytokine arrays and mRNA sequencing showed that CAR-M-c-MET produced higher levels of immune activators than control macrophages. This study provides compelling evidence for the safety and efficacy of CAR-M therapy in treating pancreatic cancer. The results demonstrate that CAR-M-c-MET significantly suppresses pancreatic cancer progression and enhances the effectiveness of cytotoxic chemotherapy. Remarkably, no discernible side effects occur. Further clinical trials are warranted in human pancreatic cancer patients.
Outpatient worsening of heart failure and mortality in transthyretin amyloid cardiomyopathy
Authors: Lawrence Zeldin, Joanna B.S. Eichler, Sergio L. Teruya, Ariel Y. Weinsaft, Alfonsina Mirabal, Margaret O. Cuomo, Kimberly Mateo, Stephen Helmke, Mathew S. Maurer
Journal: European Journal of Heart Failure (2024)
A Freeze-Dried Platelet-Derived Hemostat Decreases Bleeding in a Novel Murine Model of Type 1 Hermansky-Pudlak Syndrome
Authors: Keith Moskowitz, Lisa Booth, Molly Behan, Gustavo Nieto-Alamilla, Madison Laroche, Meredith Brown, William A. Gahl, May Christine Malicdan
Journal: Blood (2024)
Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: An Updated Analysis of a Phase 2 Study By the European Myeloma Network
Authors: Efstathios Kastritis, Giovanni O. Palladini, Meletios-Athanasios Dimopoulos, Arnaud Jaccard, Giampaolo Merlini, Foteini Theodorakakou, Despina Fotiou, Monique C Minnema, Ashutosh D. Wechalekar, Stavros Golfinopoulos, Nasia Antoniou, Giorgos Psarros, Pieter Sonneveld, Stefan Schonland
Journal: Blood (2024)
Outcomes of Therapies Following Discontinuation of Non-Covalent Bruton's Tyrosine Kinase Inhibitors for Patients with Chronic Lymphocytic Leukemia and Richter Transformation: Results from an International, Multicenter Study
Authors: Meghan C. Thompson, Seema A. Bhat, Wojciech Jurczak, Krish Patel, Nirav N. Shah, Jennifer A. Woyach, Catherine C. Coombs, Toby A. Eyre, Michal Danecki, Monika Dlugosz-Danecka, Neil Bailey, Joanna M. Rhodes, Nicole Lamanna, Andrew H. Lipsky, Jeffrey Jensen, Adam Kidwell, Eytan M. Stein, Monica Shah, Jennifer R. Brown, Andriy Derkach, Anthony R. Mato, Lindsey Roeker
Journal: Blood (2024)
Characterization of a Colony Stimulating Factor Receptor (CSF1R) Upstream Regulatory Element in Haematopoiesis
Authors: Sebastien Jacquelin, Emma Maxwell, Cameron Flegg, Yajun Liu, Isis Taylor, Ginell Ranpura, Fathima Nooru-Mohamed, Kamil A Sokolowski, Anthony Adamson, Katharine M Irvine, David A Hume
Journal: Blood (2024)
Enhanced Antitumoral Efficacy of ARI0002h CAR-T with CD28-TMD in Normal and Low BCMA Expressing Myeloma Cells
Authors: Luis Gerardo Rodríguez-Lobato, Oriol Cardus, Joan Mañé Pujol, Anthony Battram, David F. Moreno, Lorena Perez-Amill, Beatriz Martín-Antonio, Aina Oliver-Caldés, Anna De Daniel, Natalia Tovar, M Teresa Cibeira López, Laura Rosinol Dachs, Manel Juan, Alvaro Urbano-Ispizua, Carlos Fernández de Larrea
Journal: Blood (2024)
Complex Karyotype, but Not Isolated <i>TP53</i> mutation, Predicts Overall Survival in Chronic Lymphocytic Leukemia Patients in the Era of Targeted Therapy
Authors: Roberta Santos Azevedo, Mariia Mikhaleva, Kiyomi Mashima, Stephen Martindale, Stacey M. Fernandes, Svitlana Tyekucheva, Inhye E. Ahn, Matthew S. Davids, Jennifer R. Brown
Journal: Blood (2024)
Independent, International Validation and Refinement of a Machine Learning Algorithm to Classify Acute Leukemia Using Routine Laboratory Features
Authors: Amin T. Turki, Alberto Hernández Sánchez, Wellington Silva, Magdalena Karasek, Luca Guarnera, Koray Yalçin, Amir Enshaei, Marta Sobas, Dirk Reinhardt, Maria M Rivas, Deepak Kumar Mishra, Eduardo Rego, Ahmet Koc, Paola Núñez Medina, Maria Teresa Voso, Anthony Moorman, Felix Nensa, Merlin Engelke
Journal: Blood (2024)
Biological and Prognostic Subgroups of Plasmablastic Lymphoma Defined By EBV Status and <i>MYC</i> Rearrangement- an L.L.M.P.P. Study
Authors: Jasper Chun Hei Wong, Fabian Frontzek, Andrew Lytle, Brett Collinge, Laura Hilton, Susana Ben-Neriah, Graham W. Slack, Pedro Farinha, Alina S. Gerrie, Yang Li, Corinna Kosnopfel, James R. Cook, Itziar Salaverria, Elías Campo, German Ott, Andreas Rosenwald, Catalina Amador, Elaine S Jaffe, Timothy C. Greiner, Phillipp W. Raess, Joo Y. Song, Giorgio Inghirami, Dennis D. Weisenburger, Wing Chung Chan, Harald Holte, Klaus Beiske, Kai Fu, Jan Delabie, Stefania Pittaluga, Andrew L. Feldman, Kerry J. Savage, Andrew J. Mungall, Christian Steidl, Georg Lenz, Lisa M. Rimsza, Ryan Morin, David W. Scott
Journal: Blood (2024)
Efficacy and Safety of an Engineered, Liver-Tropic Adeno-Associated Virus Vector Expressing Factor IX Padua Administered with Prophylactic Glucocorticoids in Patients with Hemophilia B: A Multi-Center, Single-Arm, Phase 3 Trial
Authors: Feng Xue, Mankai Ju, Tienan Zhu, ZePing Zhou, Jing Sun, Linhua Yang, Zhenyu Yan, Hu Zhou, Xin Du, Changcheng Zheng, Xia Wu, Xiao Xiao, Renchi Yang, Lei Zhang
Journal: Blood (2024)
Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
Authors: Maria Silvina Odstrcil Bobillo, Swetha Kambhampati, Dasom Lee, Bradley D. Hunter, Ogechukwu Egini, Krish Patel, Patrick M. Reagan, David Bernasconi, Soyoung Kim, Charimar Santiago Parrilla, Tracy Krimmel, Fei Fei Liu, Debasmita Roy, Sairah Ahmed, Jennifer L. Crombie, Saurabh Dahiya, Mehdi Hamadani, Catherine J. Lee, Marcelo C. Pasquini, Mazyar Shadman, Alex F. Herrera, Matthew Frigault
Journal: Blood (2024)
A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed By Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis
Authors: Patrick Hagen, Surbhi Sidana, Terri L. Parker, Brian A. Walker, Vaishali Sanchorawala, Jeffrey A. Zonder, Taxiarchis Kourelis, Anita D'Souza, Heather J. Landau, Adam Rosenthal, Antje Hoering, Sikander Ailawadhi, Robert Z. Orlowski
Journal: Blood (2024)
Uncovering Root Causes Underlying Gaps in the Evaluation and Integration of the Latest Clinical Evidence in Congenital Thrombotic Thrombocytopenic Purpura: Key Findings from a National Hematology Care Team Survey
Authors: Azra Borogovac, Ellie Moses-Okwei, Lindsay Gurska, Emily Zyborowicz, Shelby Sullivan, Jeffrey Carter, Cherilyn Heggen
Journal: Blood (2024)
Treatment Outcomes of Adult Patients with B-Cell Acute Lymphoblastic Leukemia Relapsed after Allogeneic Stem Cell Transplant in the Era of Novel Immunochemotherapeutic Agents
Authors: Hiroaki Shimizu, Yuho Najima, Shinichi Kako, Takayoshi Tachibana, Akihiko Izumi, Susumu Tanoue, Emiko Sakaida, Takuya Miyazaki, Katsuhiro Shono, Kota Yoshifuji, Shinichiro Machida, Takashi Toya, Noriko Doki, Satoru Takada, Kaoru Hatano, Jun Kato, Satoshi Takahashi, Jun Taguchi, Shingo Yano, Yoshinobu Kanda
Journal: Blood (2024)
Comparison of the Anti-Platelet and Anti-Thrombotic Effects of the Dual SGLT1/2 Inhibitor Sotagliflozin to the Relatively Selective SGLT2 Inhibitor Empagliflozin
Authors: Livia Stanger, Pooja Yalavarthi, Mariane Flores, David Creen, Bertram Pitt, Michael Holinstat
Journal: Blood (2024)
Outcomes after Bone Marrow Versus Peripheral Blood Matched Sibling Donor Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide-Based Gvhd Prophylaxis
Authors: Muhammad Umair Mushtaq, Amir Kasaeian, Sibgha Gull Chaudhary, Muhammad Kashif Amin, Hediyeh Alemi, Naghmeh Khavandgar, Iqra Anwar, Sohaib Irfan, Matthew McGuirk, Al-Ola Abdallah, Anurag K. Singh, Mehdi Hamadani, Joseph P. McGuirk, Moazzam Shahzad
Journal: Blood (2024)
A Retrospective Cohort Study Evaluating Outcomes of Higher Risk MDS Treated with Hypomethylating Agents with or without Venetoclax Using International Working Group 2023 Response Criteria
Authors: Mihir Shukla, Chinyere Okpara, Elaine Xiang, Maher Abdul Hay, Shella Saint Fleur-Lominy, Jun Han Choi
Journal: Blood (2024)
In AML Patients Allografted in First Remission, <i>DNMT3A</i> Mutations Differentially Affect Post-Transplant Outcomes According to Karyotype, NPM1 and FLT3-ITD Mutation Status - from the EBMT-ALWP
Authors: Iman Abou Dalle, Jacques-Emmanuel Galimard, Xavier Poiré, Jaime Sanz, Anne Huynh, Nicolaus Kröger, Eva-Maria Wagner Drouet, David Burns, Matthias Eder, Bruno Lioure, Depei Wu, Jiri Mayer, Kristina Carlson, Matthias Stelljes, Matthew Collin, Mahmoud Aljurf, Arnon Nagler, Jordi Esteve, Fabio Ciceri, Ali Bazarbachi, Mohamad Mohty
Journal: Blood (2024)
Treatment Patterns and Predictors of Survival after First Line Therapy in Large B-Cell Lymphoma in a Real-World US Cohort
Authors: Joseph P. McGuirk, Mark Fesen, Scott D. Ramsey, Rony Abou-Jawde, Anthony Proli, Hil Hsu, Anik R Patel, Miguel-Angel Perales, Blythe Adamson, Jiarui Fu, Jeremy Snider
Journal: Blood (2024)
Phase 2a Study of SLS009, a Highly Selective CDK9 Inhibitor, in Combination with Azacitidine and Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia after Prior Venetoclax Treatment
Authors: Joshua F Zeidner, Omer Jamy, Bradley Christensen, Sharif S. Khan, Dragan Cicic, Tapan M. Kadia
Journal: Blood (2024)
A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)
Authors: John F. DiPersio, Guenther Koehne, Nirali N. Shah, Lea Bernard, Hyung C Suh, Divya Koura, Miguel Angel Perales, Roni Tamari, Muhammad Umair Mushtaq, Joseph E. Maakaron, Michael R. Loken, Darren A Stanizzi, Melissa M. Lee-Sundlov, Sanjana Thosar, Sharon L Hyzy, Glen D Raffel, Brenda W Cooper
Journal: Blood (2024)
Plasma Proteomic Profiling Identifies Prognostic Biomarkers in Mantle Cell Lymphoma
Authors: Tove Selvin, Patrick Nylund, Ann-Marie Ly, Anna Nikkarinen, Mattias Berglund, Kossi D Abalo, Daniel Molin, Gunilla Enblad, Peter Hollander, Mats Hellström, Ingrid Glimelius
Journal: Blood (2024)
Modeling the Initiation and Progression of Human <i>MLL</i>-Rearranged Precursor B Cell Acute Lymphoblastic Leukemia in Mice
Authors: Zhenhua Chen, Lu Yang, Lillian Sau, Zunsong Hu, Meiling Chen, Chengwu Zeng, Chao Shen, Ying Qing, Yuan Che, Dong Wu, Tingting Tang, Zhaoxu Xu, Xin He, Lianjun Zhang, Pu Cheng, Hengyou Weng, Huilin Huang, Zhaohui Gu, Gang Xiao, Xiaolan Deng, Jianjun Chen
Journal: Blood (2024)
ASXL1 Mutations in AML Are Associated with a Distinct Epigenetic State Which Highlights Vulnerabilities to Specific Epigenetic-Targeted Agents
Authors: Christopher Peter Mill, Warren C. Fiskus, Christine Birdwell, John A. Davis, Kaberi Das, Hanxi Hou, Surbhi Sharma, Koji Sasaki, Sanam Loghavi, Tapan M. Kadia, Naval Daver, Courtney D. DiNardo, Lu Wang, Kapil N. Bhalla
Journal: Blood (2024)
Daratumumab with Dose-Adjusted EPOCH Is Feasible in Newly Diagnosed Plasmablastic Lymphoma: AIDS Malignancy Consortium 105
Authors: Ariela Noy, Stefan K. Barta, Deukwoo Kwon, Robert Baiocchi, Juan Carlos Ramos, Paul Rubinstein, Amy Chadburn, Richard F. Ambinder
Journal: Blood (2024)
High-Risk Subgroups and MRD: An Updated Analysis of the Phase 3 ECHO Trial of Acalabrutinib with Bendamustine/Rituximab in Previously Untreated Mantle Cell Lymphoma
Authors: Martin Dreyling, Jiri Mayer, David Belada, Yuqin Song, Wojciech Jurczak, Jonas Paludo, Michael P. Chu, Iryna Kryachok, Laura Maria Fogliatto, Chan Y. Cheah, Marta Morawska, Juan-Manuel Sancho, Yufu Li, Caterina Patti, Cecily Forsyth, Jingyang Zhang, Robin Lesley, Safaa Ramadan, Simon Rule, Michael Wang
Journal: Blood (2024)
A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO - a Report from the Children's Oncology Group
Authors: Jessica A. Pollard, Todd A. Alonzo, Robert Gerbing, Matthew A. Kutny, Betsy Hirsch, Gordana Raca, Kasey Leger, Jennifer J. Wilkes, Aman Wadhwa, Zachary Graff, Reena Pabari, Samir Kahwash, Karen M Chisholm, Joseph Chewning, John T. Horan, Richard Aplenc, Katherine Tarlock, Sarah Menig, Olga Militano, Bonnie Ky, Chad A. Hudson, Lisa Eidenschink Brodersen, Michael R. Loken, Soheil Meshinchi, Anders Kolb, Todd M Cooper
Journal: Blood (2024)
Clinical Features and Outcomes of Localized Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma: A Dual-Center Retrospective Observational Study with a Long-Term Follow-up
Authors: Kikuaki Yoshida, Noriko Iwaki, Nobuhiko Yamauchi, Yusuke Koba, Yuko Shirouchi, Yuko Ishihara, Yuko Mishima, Shinichi Makita, Suguru Fukuhara, Wataru Munakata, Norihito Inoue, Naoko Tsuyama, Senzo Taguchi, Takashi Terauchi, Hideki Tsuji, Akiko Miyagi-Maeshima, Shigenobu Suzuki, Hiroshi Igaki, Kengo Takeuchi, Koji Izutsu, Dai Maruyama
Journal: Blood (2024)
The Anti-BCMA Antibody-Drug Conjugate Hdp-101 with a Novel Amanitin Payload Shows Promising Initial First in Human Results in Relapsed Multiple Myeloma
Authors: Robert Z. Orlowski, Shambavi Richard, Jonathan L. Kaufman, Sebastian Grosicki, Istvan Takacs, Andras Strassz, Andreas Martin Pahl, Michael Kulke, Thorsten Michael, Anette Last, Hajnalka Szaboki, Frank Richard, Oliver Schönborn-Kellenberger, Marc S. Raab
Journal: Blood (2024)
Occurrence and Predictors of Patient Reported Fertility Discussions in Non-Hodgkin Lymphoma Patients: Utilizing the Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
Authors: Nadia Toumeh, Melissa C. Larson, Bri J Negaard, Carla Casulo, Sairah Ahmed, Matthew J. Maurer, Andrew L. Feldman, Brian K. Link, Jonathon B. Cohen, Thomas M. Habermann, Dai Chihara, Izidore S. Lossos, Jonathan W. Friedberg, Brad Kahl, Peter Martin, Christopher R. Flowers, James R. Cerhan, Annalynn M Williams, Allison C. Rosenthal, Carrie A Thompson, Urshila Durani
Journal: Blood (2024)
Treg Selection from G-CSF Stimulated Donors Improves Outcomes of Immune-Suppression Free HLA-Haploidentical Hematopoietic Cell Transplantation with T Cell Adoptive Immunotherapy
Authors: Antonio Pierini, Loredana Ruggeri, Valerio Viglione, Simonetta Saldi, Rebecca Sembenico, Caridi Matteo, Francesco Zorutti, Anna Castaldo, Alessandra Cipiciani, Tiziana Zei, Roberta iacucci Ostini, Antonella Mancusi, Enrico Karim Jardini, Eni Hoxha, Adelmo Terenzi, Valeria Cardinali, Roberta La Starza, Cristina Mecucci, Andrea Velardi, Massimo Fabrizio Martelli, Maria Paola Martelli, Cynthia Aristei, Alessandra Carotti
Journal: Blood (2024)
Diagnostic Test Accuracy of Serum and Urine Immunofixation and Free Light Chains in the Diagnosis of Light Chain Amyloidosis: A Systematic Review and Meta-Analysis
Authors: Jamil Nazzal, Muayad Azzam, Hassan Kawtharany, Vishal Kukreti, Matthew D. Seftel, Aseel Alkhader, Tala Khraise, Qais Hamarsha, Hadi Khaled Abou Zeid, Iktimal Alwan, Mohammad Mahmoud AlMasri, Noor Jaber, Vaishali Sanchorawala, Joselle Cook, Jack Khouri, Angela Dispenzieri, Maria M. Picken, Maria Adela Aguirre, Hira Shaikh, Shahzad Raza, Antonia Carroll, Deborah Boedicker, Naresh Bumma, Raymond Comenzo, Noel Dasgupta, Daulath Singh, Alfredo H. De La Torre, Nitasha Sarswat, Nelson Leung, Faizi Jamal, Reem A Mustafa
Journal: Blood (2024)
A Novel Murine Model Rebalancing Coagulation Enables Gene Therapy Studies for Severe Protein C Deficiency, a Lethal Pro-Thrombotic Disorder
Authors: Sarina Levy-Mendelovich, Einat Avishai, Ben Samelson-Jones, Rima Dardik, Tami barazani-Brutman, Yael Nisgav, Tami Livnat, Gili Kenet
Journal: Blood (2024)
Large Cell Transformation in Mycosis Fungoides &amp; Sezary Syndrome: An Analysis of 445 Cases
Authors: Rishabh Lohray, Lei Feng, Auris O Huen, Iyanuoluwa Ogundipe, Luis Malpica, Bouthaina S. Dabaja, Julia Dai, Jillian R. Gunther, Chitra Hosing, Roberto N. Miranda, L. Jeffrey Medeiros, Samer A. Srour, Jeremy Ramdial, Francisco Vega, Mansoor Noorani, Amy A. Ayers, Penny Q. Fang, Luis E. Fayad, Chelsea C. Pinnix, Madeleine Duvic, Jie Xu, Christopher R. Flowers, Susan Y. Wu, Kunhwa Kim, Carlos P Torres-Cabala, Swaminathan P Iyer, Ranjit Nair
Journal: Blood (2024)
Development of ZE66-0205, a Novel MALT1 Degrader for Treatment of B-Cell Malignancies
Authors: Sara Elgamal, Casie Furby, Marissa Long, Kaytlynn Fyock, Thomas M. Sesterhenn, Megan E. Johnstone, Jianmin Pan, Shesh N. Rai, Alexander Khvat, Ruben Karapetian, Alexey Ryakhovskiy, Elena Bulanova, Vladislav Parchinsky, Nikolay Savchuk, Iain Dukes, Amy Burd, Erin K. Hertlein, John C. Byrd
Journal: Blood (2024)